• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
171645 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
0 f$ t( @" L1 W$ t( t) w+ L' \) `, d
可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
0 c4 ^9 p- o$ f, g; r: t2 j% u
8 ?4 Q0 c/ @9 s" B; A" J8 ?# q* u5 L
Sub-category:
  I7 X5 s- {$ A: FMolecular Targets
! k+ r* Y- L& C
3 ~3 n: P' D, D* t+ w! [6 l0 ~/ z( I6 B* m$ b' Y. o# A
Category:
5 ~! z4 S9 E* b, k) `2 NTumor Biology   O- X* f' _9 Q

7 ~  C% p* O! w; i, W; \' x5 T1 f, ?) [7 Y. H2 C. y
Meeting:
" d0 k# @9 I( x8 p2011 ASCO Annual Meeting , z2 a# b+ ]- f6 a  ^0 o9 J
' H/ O: l2 ]' V- Q0 o/ z4 _! P

  P3 U8 a! L2 n0 P* @Session Type and Session Title:+ Z9 e' G6 V" B7 O9 l$ o% k
Poster Discussion Session, Tumor Biology 8 h: X" O1 N; X
4 I0 Z& ~6 K5 N1 n

' i1 h: H, {( K& W; mAbstract No:& O% s) D9 H; k2 U( {6 _
10517
5 w  S7 K3 }5 u! N2 g3 u# u4 g( [/ B7 F: w

) C7 B" y! L* Z- X0 iCitation:
+ h* `( k1 d( T, e9 UJ Clin Oncol 29: 2011 (suppl; abstr 10517) $ x2 v' g* \6 n) W5 }( U

+ A3 Q2 l% i% p0 o4 ^. n) z
5 i& F9 w) l  a+ [Author(s):2 M0 |! W5 }/ e) p8 w( p, Y! w' t
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
9 {/ S3 c, j+ I% h: ~4 t# H4 x- q
  n# ?% v2 e" ~, `. `+ k7 R' N6 U* [! G9 @
$ t. O, g( }, J/ g  l! X0 Q
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
5 h1 j& F0 j0 B7 v; Y% |) I- Q# S2 O( G& I0 z9 w( {' ?% ]
Abstract Disclosures4 k8 Z) f5 P6 g% v- N* W; G+ x

3 ^- ~/ \* B/ w. J+ g. {: lAbstract:# M# `& s, ^7 }

/ r  k; n, X0 O% r8 W3 b- Y5 v+ K5 ?" ]* a2 b' R
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.9 Z# W. ^' N  X3 Z5 B$ J

% @0 q, B) v$ B) V
) N7 H/ l7 w+ j( K
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
0 c/ P2 w4 V, H没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
- M9 z0 w- K2 @* v+ q2 x4 |$ N
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 + y# l* G: @8 f* c
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。5 N3 Y8 ]& w1 l5 w9 e$ |# t
ALK一个指标医院要900多 ...

# P/ N5 P: A- d# y8 H平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
0 ]; K  r  u) g8 @. r- H# f# Z7 Z# T2 B, H- ^
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表